Zepbound vs Compounded Tirzepatide: The Real 12-Month Cost at Every Dose (October 2026)
Released: Last reviewed:
Cash-pay Zepbound costs more as your dose climbs. Most compounded programs charge the same at every dose. Here is what a first year costs both ways, priced from each seller’s own page on October 14, 2026, and what you give up for the savings.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP · Every price read on the seller’s own page October 14, 2026 · Sources cited at the end.
As of October 14, 2026, a first year of brand Zepbound bought self-pay through LillyDirect costs about $5,087–$5,637. That is 13 four-week fills titrating to 5 mg, or to 7.5–15 mg, with every refill on time. Compounded tirzepatide from flat-priced programs costs $1,027–$2,028 for twelve months at any dose. The gap is roughly $3,000–$4,600 a year. Compounded tirzepatide is not FDA-approved.
How Zepbound self-pay is priced
Lilly’s self-pay price for the Zepbound KwikPen depends on the dose. (The page says the $299 starting price also applies to a one-month supply of vials; it does not print vial prices for higher doses, so the figures below are KwikPen prices.) The prices, read October 14, 2026:
- 2.5 mg: $299 per fill
- 5 mg: $399 per fill
- 7.5 mg to 15 mg: $449 per fill with Lilly’s purchase offer, which requires each refill within 45 days of the last delivery. Without the offer, 7.5 mg is $499 and 10–15 mg is $699.
Two details change the annual math. First, a Zepbound “month” is four weekly doses, or 28 days. A year of weekly injections therefore takes 13 fills, not 12. Second, the savings terms run through December 31, 2026. Lilly reports third-quarter earnings on October 29, and 2027 terms may follow; we will re-price this page when they are published.
Under the FDA label, Zepbound starts at 2.5 mg weekly for four weeks, then 5 mg. The dose can rise in 2.5 mg steps after at least four weeks on the current dose, to a maintenance dose of 5, 10 or 15 mg.
Year one on Zepbound, dose by dose
| Maintenance dose | Fill schedule | Year-one total | Per month (÷12) |
|---|---|---|---|
| 5 mg | 1 × $299 (2.5 mg) + 12 × $399 | $5,087 | $424 |
| 10 mg | $299 + $399 + 11 × $449 | $5,637 | $470 |
| 15 mg | $299 + $399 + 11 × $449 | $5,637 | $470 |
| 15 mg, every refill late | $299 + $399 + $499 (7.5 mg) + 10 × $699 | $8,187 | $682 |
Above 5 mg the price no longer rises: 7.5 mg (a titration step), 10 mg and 15 mg all cost $449 per fill. One late refill costs $50 more at 7.5 mg and $250 more at 10–15 mg. Buying late every time on the way to 15 mg would add $2,550 over the year.
Year one on compounded tirzepatide
Compounded programs bill by the calendar month, and most of the programs below print a price that stays the same at every dose. These are the lowest standing and conditional options in our price index, read October 14, 2026:
| Program | How you pay | 12-month total | Changes with dose? |
|---|---|---|---|
| Collective | $69/month + $199 yearly membership | $1,027 | No (“Same price, any dose”) |
| Embody | 12-month supply paid at once; all payments final | $1,428 | Not stated |
| SnagRx | $119 promotional monthly (list $349) | $1,428 only if the promotion lasts all year | No |
| NexLife | $139/month on a 12-month plan, charged monthly; coaching and nutrition plan included | $1,668 | No |
| NexLife, no commitment | $169 month to month | $2,028 | No |
| Henry Meds (for comparison) | $349/month for a sublingual compounded tablet; no FDA-approved oral tirzepatide exists | $4,188 | Not stated |
Against Zepbound’s $5,637 at 7.5–15 mg, these programs save about $3,600–$4,600 a year. At a 5 mg maintenance dose the saving is about $3,000–$4,000. Henry Meds is the exception: at $349 a month it is closer to brand pricing than to the compounded field.
Cost per milligram: why the gap grows at higher doses
Price per milligram shows what flat pricing is worth. A four-week Zepbound fill at 15 mg holds 60 mg of tirzepatide for $449, about $7.48 per mg. At 2.5 mg the same $299 buys 10 mg, or $29.90 per mg. A compounded program charging a flat $119 a month supplies about 65 mg a month at a 15 mg weekly dose (4.33 weeks), or roughly $1.83 per mg. At 2.5 mg the same $119 works out to about $11 per mg. Flat pricing favors people on higher maintenance doses. Dose-tiered brand pricing favors people who stay at 2.5–5 mg.
One caution on that comparison. A milligram of compounded tirzepatide is not tested to the same standard as a milligram of Zepbound. Brand pens and vials are made under FDA cGMP with approved specifications. Compounded vials vary by pharmacy, and the FDA does not review them for safety, effectiveness or quality.
Two worked examples
Maria, maintenance at 5 mg. Her prescriber keeps her at 5 mg after the first month. On Zepbound self-pay she pays $299 once and then $399 twelve times: $5,087 for the year. On NexLife’s 12-month plan she pays $1,668 and gets coaching and a nutrition plan. On Collective she would pay $1,027 including the yearly membership. Her saving against brand is about $3,420–$4,060. Because she stays on a low dose, she gets the least benefit from flat pricing.
James, maintenance at 15 mg. He titrates through 7.5, 10 and 12.5 mg to 15 mg by month six. On Zepbound self-pay, with every refill inside 45 days, he pays $299, $399 and then $449 eleven times: $5,637. If two refills slip past 45 days at 15 mg, he pays $500 more. On a flat compounded plan his price never moves: $1,668 at NexLife on twelve months, or $1,027 at Collective. His saving is about $3,970–$4,610. Flat pricing is worth the most to him.
In both cases the cash difference is real. So is the trade-off: an approved, cGMP-made product with trial data on one side, and a compounded product whose legal footing the FDA is narrowing on the other.
What the extra $3,000–$4,600 buys
- An FDA-approved product. Zepbound’s efficacy comes from the SURMOUNT trials; SURMOUNT-1 reported 20.9% mean weight loss at 72 weeks on 15 mg. No compounded product has trial data of its own.
- Supply that does not depend on enforcement. Compounding is under pressure. The FDA warned Empower Pharmacy in September (what that means), and the 503B exclusion proposed in April is still pending. A brand prescription is not exposed to either.
- Coverage paths. Medicare Part D enrollees who qualify for the GLP-1 Bridge pay $50 a month, or $600 a year, through 2027. Some employer plans still cover Zepbound, although large-employer coverage of obesity drugs fell from 72% to 60% in a 2026 survey.
What the lower price buys is flat pricing at maintenance doses and, with some programs, clinician oversight, coaching and shipping in one bill. You also accept a product that is not FDA-approved and a legal pathway that the FDA is narrowing.
The middle option: the Foundayo pill
Lilly’s oral GLP-1, Foundayo (orforglipron), is FDA-approved and priced between the two. On LillyDirect it costs $149 at 0.8 mg, $149 at 2.5 mg and $199 at 5.5 mg; the 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026. It is $299 at 9 mg, and at 14.5 or 17.2 mg with refills within 45 days. At $299 a month, a year at the higher doses costs about $3,600. Its average weight loss in trials is lower than tirzepatide’s; see oral GLP-1 pill vs compounded tirzepatide.
How to choose
- Insured or on Medicare? Check coverage and the GLP-1 Bridge first. A $50 copay beats every cash price on this page.
- Paying cash and want FDA approval? Budget about $5,100–$5,700 for year one, refill within 45 days, and watch for 2027 terms after December 31.
- Paying cash and price-sensitive? Compare compounded programs on the standing monthly price, whether the price is flat at your dose, the named pharmacy and the refund terms, not on the lowest sticker. Our value ranking scores six of those checks.
- Switching between them? Doses are not interchangeable across products without your prescriber’s plan. See switching providers without a dose gap.
Frequently asked questions
How much does Zepbound cost without insurance per year?
Through LillyDirect, about $5,087 for a first year titrating to 5 mg and $5,637 for 7.5–15 mg. That assumes 13 four-week fills with every refill within 45 days, at prices read October 14, 2026.
Is compounded tirzepatide cheaper than Zepbound at every dose?
Among the flat-priced programs we track, yes: $86–$169 a month against $299–$449. The gap is smallest at 2.5 mg and largest at 7.5–15 mg.
Why are there 13 Zepbound fills in a year?
Each fill is four weekly doses (28 days), and 52 weeks divided by four is 13. Compounded programs bill per calendar month, so they charge 12 times a year.
Will Zepbound self-pay prices change in 2027?
Possibly. Lilly’s current savings terms run through December 31, 2026. We will update this page when 2027 prices are published.
Is the cheapest compounded program the best value?
Not always. Check whether the price is a standing rate or a promotion, whether it is prepaid and non-refundable, whether it rises with dose, and which pharmacy fills it. Our value ranking shows how each program scores.
Sources
- Lilly: Zepbound coverage and savings, self-pay prices and terms (read October 14, 2026).
- Zepbound (tirzepatide) U.S. Prescribing Information, Eli Lilly and Company: dosage and administration.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- LillyDirect: Foundayo self-pay prices (read October 14, 2026).
- CNBC: Medicare GLP-1 Bridge enrollment (September 21, 2026).
- Insurance Business: employer GLP-1 coverage survey (October 13, 2026).
- Lilly investor relations: Q3 2026 earnings date.
Not medical advice. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company). Dosing decisions belong to a licensed clinician.